CVS' Health Services segment posts $43B in revenues as specialty pharmacy and Caremark deals drive 2025 growth prospects.

CVS Caremark identified GLP-1 drugs and Humira as points of contention, but the State Health Plan says that mischaracterizes ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

Starting July 1, Caremark will list Novo Nordisk’s NVO Wegovy as the preferred GLP-1 medicine on its largest commercial template formularies. The Novo Nordisk partnership echoes CVS’ launch of ...

CVS Caremark is the plan’s pharmacy benefit manager ... the manufacturer of GLP-1s Wegovy and Saxenda. That saved the state $539 off the $1,347 list price for each prescription of both drugs ...

NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.

The healthcare sector is dominated by massive players, but few are as influential as UnitedHealth Group Incorporated UNH and ...

Earlier this month, Novo announced that CVS Caremark chose Wegovy to be its preferred GLP-1 medication for obesity and weight-loss. 2 This policy will go into effect at the start of July. In a press ...